Nexlizet (Bempedoic Acid 180 mg/Ezetimibe 10 mg)
Administer one tablet orally once daily, with or without food, and check lipid levels within 8-12 weeks of initiation. 1
Dosing and Administration
- Standard dose: One tablet (180 mg bempedoic acid/10 mg ezetimibe) once daily
- Timing: Can be taken with or without food
- Swallow whole: Do not crush or split the tablet
- Missed dose: Take as soon as remembered; do not double the next dose 1
Special Timing Considerations
If patient is on bile acid sequestrants (cholestyramine, colesevelam, colestipol): Administer Nexlizet either ≥2 hours before OR ≥4 hours after the bile acid sequestrant to avoid binding interactions 1
Monitoring Requirements
Lipid Monitoring
- Initial assessment: Check lipid panel 8-12 weeks after starting therapy 1
- Ongoing: Monitor periodically to assess goal attainment based on risk category
Uric Acid Monitoring
- Baseline and periodic assessment: Check serum uric acid when clinically indicated, particularly if symptoms of hyperuricemia develop 1
- Rationale: Bempedoic acid inhibits renal tubular OAT2, increasing uric acid levels in 26% of treated patients (vs 9.5% placebo) 1
- Timing: Increases typically occur within first 4 weeks and persist during treatment
Liver Enzyme Monitoring
- Monitor hepatic transaminases as clinically indicated, particularly if used with statins 1
Clinical Monitoring
- Tendon symptoms: Assess for tendon pain, swelling, or rupture at each visit
- Gout symptoms: Monitor for new-onset or worsening gout (occurred in 3.2% vs 2.2% placebo in cardiovascular outcomes trial) 1
Indications and Patient Selection
FDA-Approved Indications 1
Adjunct to diet and exercise to reduce LDL-C in adults with:
- Primary hypercholesterolemia
- Heterozygous familial hypercholesterolemia (HeFH)
Cardiovascular risk reduction (bempedoic acid component):
- Reduce risk of MACE (CV death, MI, stroke, coronary revascularization) in adults at increased risk who are unable to take recommended statin therapy (including those not taking a statin)
Guideline-Based Use
According to 2026 ACC/AHA guidelines, ezetimibe (a component of Nexlizet) should be added in specific scenarios 2:
For secondary prevention (clinical ASCVD):
- Not at very high risk: Add ezetimibe if LDL-C remains ≥70 mg/dL on maximally tolerated statin (Class 2a, LOE B-R) 2
- At very high risk: Add ezetimibe and/or PCSK9 inhibitor if LDL-C remains ≥55 mg/dL on maximally tolerated statin (Class 1, LOE A) 2
For severe hypercholesterolemia (LDL-C ≥190 mg/dL):
- Add ezetimibe on maximally tolerated statin to achieve goals based on risk category (Class 1, LOE B-R/B-NR) 2
Contraindications
Absolute contraindication 1:
- Known hypersensitivity to ezetimibe, bempedoic acid, or any excipients
- Serious reactions reported include anaphylaxis, angioedema, rash, and urticaria
Warnings and Precautions
Hyperuricemia (Most Common Concern)
- Occurs in 26% of patients (vs 9.5% placebo) 1
- Mean increase: 0.8 mg/dL after 12 weeks
- Management: Initiate urate-lowering therapy as appropriate; advise patients to report symptoms
Tendon Rupture (Critical Safety Issue)
- Occurred in 1.2% of patients in cardiovascular outcomes trial (vs 0.7% placebo) 1
- Sites: Rotator cuff, biceps tendon, Achilles tendon
- Timing: Within weeks to months of starting therapy
- Action: Discontinue at first sign of tendon rupture
- Avoid in: Patients with history of tendon disorders or prior tendon rupture
Hepatotoxicity
- Persistent elevations in transaminases may occur, particularly with concomitant statin use 1
- Monitor based on statin recommendations when used in combination
Pregnancy
- Contraindicated: Based on mechanism of action, may cause fetal harm 1
Drug Interactions
Statin Dose Limitations (Critical)
- Simvastatin: Avoid doses >20 mg when combined with Nexlizet 1
- Pravastatin: Avoid doses >40 mg when combined with Nexlizet 1
Other Interactions
- Cyclosporine: Monitor cyclosporine concentrations 1
- Fibrates: If cholelithiasis suspected with fenofibrate, consider alternative therapy 1
- Bile acid sequestrants: Timing separation required (see above) 1
Common Adverse Reactions
Primary hypercholesterolemia trials (≥2% and more than placebo) 1:
- Upper respiratory tract infection
- Muscle spasms
- Hyperuricemia
- Back pain
- Abdominal pain/discomfort
- Bronchitis
- Pain in extremity
- Anemia
- Elevated liver enzymes
- Diarrhea
Cardiovascular outcomes trial (≥2% and more than placebo) 1:
- Hyperuricemia (16.4% vs 8.2%)
- Renal impairment
- Anemia
- Elevated liver enzymes
- Muscle spasms
- Gout (3.2% vs 2.2%)
- Cholelithiasis
Clinical Efficacy Context
While Nexlizet contains ezetimibe (which has cardiovascular outcomes data from IMPROVE-IT) 3, the specific fixed-dose combination with bempedoic acid provides robust LDL-C lowering. Research on rosuvastatin/ezetimibe combinations (a different but related combination) demonstrates 58-63% LDL-C reductions with combination therapy versus 45-56% with statin monotherapy 4, 5. The bempedoic acid component adds cardiovascular risk reduction specifically for statin-intolerant patients 1.
Key Clinical Pearls
- First-line use: Reserve for patients who cannot achieve LDL-C goals on maximally tolerated statin therapy or who are statin-intolerant
- Uric acid management: Proactively monitor and treat hyperuricemia to prevent gout flares
- Tendon vigilance: Educate patients to report any tendon pain immediately; discontinue if rupture suspected
- Timing with bile acid sequestrants: Critical to maintain 2-hour separation to ensure absorption